# Portage Biotech Inc. (PRTG)

Source: https://www.quantisnow.com/company/PRTG
Generated: 2026-11-10T22:26:36.021Z

- Ticker: PRTG
- Exchange: NASDAQ
- Sector: Energy
- Industry: Oil & Gas Production
- Website: portagebiotech.com

## About

Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses on nanolipogel technology for use in immune-oncology; and antibodies against a novel T-cell for use as a monotherapy and combination therapy for solid and haematological malignancies. In addition, the company develops antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments; and FOXO4-P53 modulator and C-RAF inhibitor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.

## Latest PRTG news and filings

- 2025-09-05 21:01 UTC [SEC Form 424B3] [SEC Form 424B3 filed by Portage Biotech Inc.](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-portage-biotech-inc-6191997)
- 2025-09-04 21:00 UTC [SEC Form 6-K] [SEC Form 6-K filed by Portage Biotech Inc.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-portage-biotech-inc-6190477)
- 2025-09-03 21:14 UTC [SEC Form 424B5] [SEC Form 424B5 filed by Portage Biotech Inc.](https://www.quantisnow.com/insight/sec-form-424b5-filed-by-portage-biotech-inc-6188569)
- 2025-09-03 19:46 UTC [SEC Form 424B3] [SEC Form 424B3 filed by Portage Biotech Inc.](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-portage-biotech-inc-6187690)
- 2025-09-03 13:22 UTC [SEC Form 6-K] [SEC Form 6-K filed by Portage Biotech Inc.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-portage-biotech-inc-6187395)
- 2025-09-03 13:00 UTC [Public Offering] [AlphaTON Capital Corp Launches TON Digital Asset Treasury Strategy for the Telegram Ecosystem](https://www.quantisnow.com/insight/alphaton-capital-corp-launches-ton-digital-asset-treasury-strategy-for-6187319)
- 2025-08-01 21:24 UTC [SEC Form S-8] [SEC Form S-8 filed by Portage Biotech Inc.](https://www.quantisnow.com/insight/sec-form-s-8-filed-by-portage-biotech-inc-6143379)
- 2025-07-28 13:00 UTC [SEC Form 424B3] [SEC Form 424B3 filed by Portage Biotech Inc.](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-portage-biotech-inc-6133979)
- 2025-07-25 20:31 UTC [SEC Form 424B3] [SEC Form 424B3 filed by Portage Biotech Inc.](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-portage-biotech-inc-6133191)
- 2025-07-25 20:25 UTC [SEC Form 6-K] [SEC Form 6-K filed by Portage Biotech Inc.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-portage-biotech-inc-6133135)
- 2025-07-25 20:20 UTC [SEC Form 20-F filed by Portage Biotech Inc.](https://www.quantisnow.com/insight/sec-form-20-f-filed-by-portage-biotech-inc-6133124)
- 2025-07-25 20:15 UTC [Public Offering] [Portage Biotech Reports Results for Fiscal Year Ended March 31, 2025](https://www.quantisnow.com/insight/portage-biotech-reports-results-for-fiscal-year-ended-march-31-6133066)
- 2025-06-27 20:25 UTC [SEC Form 424B3] [SEC Form 424B3 filed by Portage Biotech Inc.](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-portage-biotech-inc-6101979)
- 2025-06-27 20:20 UTC [SEC Form 6-K] [SEC Form 6-K filed by Portage Biotech Inc.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-portage-biotech-inc-6101946)
- 2025-06-27 20:15 UTC [SEC Form 424B5] [SEC Form 424B5 filed by Portage Biotech Inc.](https://www.quantisnow.com/insight/sec-form-424b5-filed-by-portage-biotech-inc-6101901)
- 2025-06-25 11:26 UTC [SEC Form 424B3] [SEC Form 424B3 filed by Portage Biotech Inc.](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-portage-biotech-inc-6098239)
- 2025-06-25 11:15 UTC [SEC Form 6-K] [SEC Form 6-K filed by Portage Biotech Inc.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-portage-biotech-inc-6098234)
- 2025-06-25 11:00 UTC [Portage Biotech Regains Full Compliance with Nasdaq Continued Listing Requirements](https://www.quantisnow.com/insight/portage-biotech-regains-full-compliance-with-nasdaq-continued-listing-requirements-6098207)
- 2025-06-09 11:14 UTC [SEC Form 424B3] [SEC Form 424B3 filed by Portage Biotech Inc.](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-portage-biotech-inc-6077548)
- 2025-06-09 11:00 UTC [SEC Form 6-K] [SEC Form 6-K filed by Portage Biotech Inc.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-portage-biotech-inc-6077506)
- 2025-06-09 10:00 UTC [Portage Biotech and Compedica Stock-for-Stock Exchange](https://www.quantisnow.com/insight/portage-biotech-and-compedica-stock-for-stock-exchange-6077411)
- 2025-05-29 20:40 UTC [SEC Form 424B3] [SEC Form 424B3 filed by Portage Biotech Inc.](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-portage-biotech-inc-6063566)
- 2025-05-29 20:30 UTC [SEC Form 6-K] [SEC Form 6-K filed by Portage Biotech Inc.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-portage-biotech-inc-6063449)
- 2025-05-15 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Portage Biotech Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-portage-biotech-inc-6040429)
- 2025-05-12 20:38 UTC [Amendment: SEC Form F-3/A filed by Portage Biotech Inc.](https://www.quantisnow.com/insight/amendment-sec-form-f-3a-filed-by-portage-biotech-inc-6033549)
- 2025-05-03 00:18 UTC [SEC Form F-3 filed by Portage Biotech Inc.](https://www.quantisnow.com/insight/sec-form-f-3-filed-by-portage-biotech-inc-6016842)
- 2025-04-28 10:20 UTC [SEC Form 424B3] [SEC Form 424B3 filed by Portage Biotech Inc.](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-portage-biotech-inc-6003585)
- 2025-04-28 10:10 UTC [SEC Form 6-K] [SEC Form 6-K filed by Portage Biotech Inc.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-portage-biotech-inc-6003572)
- 2025-04-28 10:00 UTC [Portage Biotech Reports Confirmatory Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7](https://www.quantisnow.com/insight/portage-biotech-reports-confirmatory-preclinical-results-in-mesothelioma-supporting-first-in-human-6003493)
- 2025-03-27 20:37 UTC [SEC Form 424B3] [SEC Form 424B3 filed by Portage Biotech Inc.](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-portage-biotech-inc-5963446)
- 2025-03-27 20:25 UTC [SEC Form 6-K] [SEC Form 6-K filed by Portage Biotech Inc.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-portage-biotech-inc-5963283)
- 2025-03-27 20:15 UTC [Portage Biotech Reports Promising Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7](https://www.quantisnow.com/insight/portage-biotech-reports-promising-preclinical-results-in-mesothelioma-supporting-first-in-human-5963134)
- 2025-03-13 20:34 UTC [SEC Form 424B3] [SEC Form 424B3 filed by Portage Biotech Inc.](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-portage-biotech-inc-5943539)
- 2025-03-13 20:15 UTC [SEC Form 6-K] [SEC Form 6-K filed by Portage Biotech Inc.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-portage-biotech-inc-5943261)
- 2025-03-12 12:20 UTC [SEC Form 424B3] [SEC Form 424B3 filed by Portage Biotech Inc.](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-portage-biotech-inc-5940030)
- 2025-03-12 12:10 UTC [SEC Form 6-K] [SEC Form 6-K filed by Portage Biotech Inc.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-portage-biotech-inc-5940011)
- 2025-03-12 12:00 UTC [Portage Biotech Resumes Enrollment in Final Cohort of Dose Escalation for Port-6 in ADPORT-601 Trial](https://www.quantisnow.com/insight/portage-biotech-resumes-enrollment-in-final-cohort-of-dose-escalation-5939986)
- 2025-02-12 21:25 UTC [SEC Form 424B3] [SEC Form 424B3 filed by Portage Biotech Inc.](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-portage-biotech-inc-5884887)
- 2025-02-12 21:20 UTC [SEC Form 6-K] [SEC Form 6-K filed by Portage Biotech Inc.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-portage-biotech-inc-5884837)
- 2025-02-12 21:15 UTC [Portage Biotech Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements](https://www.quantisnow.com/insight/portage-biotech-receives-extension-of-time-to-attain-compliance-with-5884724)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/PRTG
- Earnings history: https://www.quantisnow.com/earnings/PRTG
- Dividend history: https://www.quantisnow.com/dividends/PRTG
- Insider transactions: https://www.quantisnow.com/insiders/PRTG
- Options chain: https://www.quantisnow.com/options/PRTG
- SEC 8-K filings only: https://www.quantisnow.com/company/PRTG/8-k
- RSS and alerts for PRTG: https://www.quantisnow.com/docs/rss-feeds.md